Arvinas has been granted a patent for bifunctional compounds that target Rapidly Accelerated Fibrosarcoma (RAF) proteins for degradation. The compounds contain ligands for E3 ubiquitin ligases and RAF proteins, offering a broad range of pharmacological activities for treating diseases caused by protein aggregation or activation. GlobalData’s report on Arvinas gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Arvinas, Cancer treatment biomarkers was a key innovation area identified from patents. Arvinas's grant share as of May 2024 was 18%. Grant share is based on the ratio of number of grants to total number of patents.
Bifunctional compound for degrading/inhibiting raf target protein
The granted patent (Publication Number: US11986531B2) discloses a bifunctional compound with a specific chemical structure, ULM-L-PTM, along with various derivatives and configurations. The compound can be in the form of a pharmaceutically acceptable salt, enantiomer, or stereoisomer, with specific selections for XPTM1, XPTM2, XPTM3, XPIM4, XPTM5, and XPTM6. Additionally, the compound includes variations where RPTM9, RPTM7, RPTM8, RPTM10, and the PTM group are interconnected to form bicyclic groups within the chemical structure.
Furthermore, the patent covers the selection criteria for the PTM and ULM groups, along with the chemical linker group (L) that connects them. The chemical linker group (L) includes a wide range of structures, such as alkyl, cycloalkyl, aryl, and heteroaryl, each optionally substituted with various functional groups. The patent also extends to pharmaceutical compositions containing the bifunctional compound and a carrier, as well as methods for treating diseases associated with BRaf accumulation and aggregation. The diseases mentioned include renal cell carcinoma, pancreatic cancer, colorectal cancer, lung cancer, ovarian cancer, thyroid cancer, prostate cancer, and melanoma, among others, highlighting the potential therapeutic applications of the disclosed compound.
To know more about GlobalData’s detailed insights on Arvinas, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
